Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6

Peter Iversen; Jan-Erik Johansson; Pär Lodding; Olavi Lukkarinen; Per Lundmo; Peter Klarskov; Teuvo L J Tammela; Ilker Tasdemir; Tom Morris; Kevin Carroll; Scandinavian Prostatic Cancer Group

Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6

Peter Iversen
, Jan-Erik Johansson
, Pär Lodding
, Olavi Lukkarinen
, Per Lundmo
, Peter Klarskov
, Teuvo L J Tammela
, Ilker Tasdemir
, Tom Morris
, Kevin Carroll
, Scandinavian Prostatic Cancer Group

97 Citationer (Scopus)

Abstract

We evaluated the benefits of adding 150 mg bicalutamide to standard care, that is radical prostatectomy, radiotherapy or watchful waiting (WW), in patients with localized or locally advanced prostate cancer.

Originalsprog	Engelsk
Tidsskrift	Journal of Urology
Vol/bind	172
Udgave nummer	5 Pt 1
Sider (fra-til)	1871-6
Antal sider	6
ISSN	0022-5347
Status	Udgivet - 1 nov. 2004

Fingeraftryk

Dyk ned i forskningsemnerne om 'Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Iversen, P., Johansson, J.-E., Lodding, P., Lukkarinen, O., Lundmo, P., Klarskov, P., Tammela, T. L. J., Tasdemir, I., Morris, T., Carroll, K., & Scandinavian Prostatic Cancer Group (2004). Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. Journal of Urology, 172(5 Pt 1), 1871-6.

Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. / Iversen, Peter; Johansson, Jan-Erik; Lodding, Pär et al.
I: Journal of Urology, Bind 172, Nr. 5 Pt 1, 01.11.2004, s. 1871-6.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning

Iversen, P, Johansson, J-E, Lodding, P, Lukkarinen, O, Lundmo, P, Klarskov, P, Tammela, TLJ, Tasdemir, I, Morris, T, Carroll, K & Scandinavian Prostatic Cancer Group 2004, 'Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6', Journal of Urology, bind 172, nr. 5 Pt 1, s. 1871-6.

@article{df2fe89b1d014466887676bee8883737,

title = "Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6",

abstract = "We evaluated the benefits of adding 150 mg bicalutamide to standard care, that is radical prostatectomy, radiotherapy or watchful waiting (WW), in patients with localized or locally advanced prostate cancer.",

author = "Peter Iversen and Jan-Erik Johansson and P{\"a}r Lodding and Olavi Lukkarinen and Per Lundmo and Peter Klarskov and Tammela, \{Teuvo L J\} and Ilker Tasdemir and Tom Morris and Kevin Carroll and \{Scandinavian Prostatic Cancer Group\}",

year = "2004",

month = nov,

day = "1",

language = "English",

volume = "172",

pages = "1871--6",

journal = "Journal of Urology",

issn = "0022-5347",

publisher = "Wolters Kluwer Health",

number = "5 Pt 1",

}

TY - JOUR

T1 - Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6

AU - Iversen, Peter

AU - Johansson, Jan-Erik

AU - Lodding, Pär

AU - Lukkarinen, Olavi

AU - Lundmo, Per

AU - Klarskov, Peter

AU - Tammela, Teuvo L J

AU - Tasdemir, Ilker

AU - Morris, Tom

AU - Carroll, Kevin

AU - Scandinavian Prostatic Cancer Group

PY - 2004/11/1

Y1 - 2004/11/1

N2 - We evaluated the benefits of adding 150 mg bicalutamide to standard care, that is radical prostatectomy, radiotherapy or watchful waiting (WW), in patients with localized or locally advanced prostate cancer.

AB - We evaluated the benefits of adding 150 mg bicalutamide to standard care, that is radical prostatectomy, radiotherapy or watchful waiting (WW), in patients with localized or locally advanced prostate cancer.

M3 - Journal article

C2 - 15540741

SN - 0022-5347

VL - 172

SP - 1871

EP - 1876

JO - Journal of Urology

JF - Journal of Urology

IS - 5 Pt 1

ER -